Cytokinetics (CYTK) Tops Q2 EPS by 13c

Cytokinetics (NASDAQ: CYTK) reported Q2 EPS of ($1.50), $0.13 better than the analyst estimate of ($1.63). Revenue for the quarter came in at $28.6 million versus the consensus estimate of $17.09 million.

For earnings history and earnings-related data on Cytokinetics (CYTK) click here.

You May Also Be Interested In

• Rockstar Energy founder seeks CEO role at Celsius Holdings
• Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
• Chevron Sees Lower End Of $18-$19B Capex Guidance At Yr End - Bloomberg